18 results about "Therapy radiation" patented technology

The present invention relates to parenteral pharmaceutical compositions of suitable Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, particularly to Desidustat or suitable pharmaceutically acceptable salts thereof. The invention also relates to processes for preparing such compositions. The present invention also relates to the development of therapeutic compound for the treatment of radiation induced toxicity. Specifically, present invention relates to use of Desidustat or its pharmaceutically acceptable salt or oral and parenteral pharmaceutical composition thereof for the treatment of radiation induced toxicity.

The invention relates to the technical field of ion beam irradiation treatment radiation protection, and provides a treatment room radiation shielding system and method based on a rotating beam line, and the system comprises a central equipment room which is internally provided with rotatable treatment equipment; the plurality of treatment rooms are arranged around the central equipment room, and each treatment room is used for treating a patient; the radiation shielding wall body comprises a shielding partition wall and a shielding enclosure wall, the shielding partition wall is arranged between the adjacent treatment rooms, and the shielding enclosure wall is arranged on the periphery of the treatment rooms; a radiation attenuation channel communicated with the treatment room is defined by the shielding partition wall and the shielding enclosing wall. According to the treatment room radiation shielding system based on the rotating beam wire, the radiation attenuation channel communicated with the treatment room is defined by the shielding partition wall and the shielding enclosing wall, the space utilization rate is improved, and the limited space radiation shielding problem of the treatment room is solved.

The invention discloses a product for treating radiation damage. According to the application, GP532 is subjected to random mutation, a phage mutation library is established, and the mutation library is activated and screened by using TLR5-dependent NF-kappa B, so that 9E1 is obtained. 9E1 shows dose-dependent stimulation of TLR5 dependent NF-kB activation in vitro; an effective prevention effect is shown in an in-vivo mouse radiation injury model, and a new way is provided for effective treatment of radiation injury.

The present invention relates to parenteral pharmaceutical compositions of suitable Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, particularly to Desidustat or suitable pharmaceutically acceptable salts thereof. The invention also relates to processes for preparing such compositions. The present invention also relates to the development of therapeutic compound for the treatment of radiation induced toxicity. Specifically, present invention relates to use of Desidustat or its pharmaceutically acceptable salt or oral and parenteral pharmaceutical composition thereof for the treatment of radiation induced toxicity.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The present invention relates to a method and apparatus for multi-criteria optimization of radiation therapy plans. A control circuit accesses an optimized radiation therapy plan developed using corresponding utility functions corresponding to a plurality of metrics, and generates an approximation of the corresponding utility functions. The control circuit repeatedly selectively perturbs the approximation only with respect to a different subset of the plurality of metrics each time to generate a corresponding plurality of perturbed utility functions, and generates a plurality of supplemental optimized radiation therapy plans each time from a corresponding different one of the plurality of perturbed utility functions. The control circuit then employs the plurality of supplemental optimized radiation therapy plans and the optimized radiation therapy plan as a multi-criteria optimization workspace for a user to explore in selecting a particular optimized radiation therapy plan for employment in administering therapeutic radiation to a particular patient.

The application discloses a kind of targeted nanomedicine for treating radiation-resistant NSCLC and its preparation method and application, and belongs to the medical technical field, wherein the preparation method of targeted nanomedicine includes the following steps: using NaGdF4 as core, mesoporous silica as carrier, NaGdF4 is coated, and radio-sensitizing nanomaterial is obtained;Radio-sensitizing nanomaterial is co-incubated with PD-1 protein, and the targeted nanomedicine for treating radiation-resistant NSCLC is obtained.The application regulates radiation-resistant NSCLC tumor immune microenvironment by constructing radiosensitizing nano platform and loading PD-1 protein, controls the proliferation, migration and invasion of radiation-resistant NSCLC cells, successfully reverses the radioresistance of NSCLC, and significantly enhances the response of resistant cells to radiotherapy.The method provides valuable insights for developing targeted nanotherapeutic drugs to effectively treat NSCLC.

Disclosed is use of Cordyceps sinensis MBF1 in the preparation of a health product or drug for preventing and / or treating radiation injury, particularly in the preparation of a health product or drug for preventing and / or treating intestinal radiation injury and / or hematopoietic radiation injury caused by ionizing radiation. Cordyceps sinensis MBF1 can significantly ameliorate symptoms caused by intestinal radiation injury, such as shortened colon length, small intestinal tissue injury, and elevated small intestinal inflammation level, ameliorate symptoms caused by hematopoietic radiation injury, such as reduced white blood cell count, reduced spleen index, and / or reduced thymus index, and can be used as a health product or drug for preventing and treating radiation injury, particularly intestinal radiation injury and / or hematopoietic radiation injury, thereby addressing the current lack of effective health products or drugs for the clinical treatment of intestinal radiation injury and / or hematopoietic radiation injury. In addition, the present disclosure provides a new idea and strategy for developing an anti-radiation injury health product or drug and demonstrates important scientific significance and clinical application value.

The invention discloses application of chicoric acid in preparation of a medicine for improving hematopoietic injury caused by radiation, and belongs to the technical field of biological medicine. In order to solve the problem that an effective intervention means for hematopoietic system injury caused by ionizing radiation is lacked in the prior art, the invention provides application of chicoric acid in preparation of drugs for improving hematopoietic injury caused by radiation, and shows a dual protection mechanism of chicoric acid acting on a hematopoietic differentiation key regulation node. The hematopoietic function is synergistically improved by regulating EPO and other hematopoietic factors and progenitor cell populations, meanwhile, the anti-oxidation effect is achieved, radiation damage is relieved, definite active ingredients and action targets are provided for preparing the medicine for preventing and treating hematopoietic damage caused by radiation, and the application value of clinical transformation is achieved.

The invention relates to a magnetic resonance imaging radiotherapy system capable of reducing interference on treatment radiation. The system comprises: a magnetic resonance imager (110) comprising a magnet (120) surrounding an aperture (130); a radiation therapy device (140) configured for radiating a therapy beam (160) having a respective radial beam path towards the aperture (130) from a plurality of locations around a longitudinal axis (150) of the aperture; a cold head (170) positioned outside the beam path; and a thermally conductive cooling section (180) in thermal connection with the cold head (170). The cooling section (180) extends azimuthally about a longitudinal axis (150) of the bore. The cooling section (180) is positioned to intersect the beam path, and the width (w) of the cooling section is greater than the maximum width of the treatment beam (180). Preferably, the attenuation of the treatment beam (160) caused by the cooling section (180) is constant between respective beam paths from different positions around the longitudinal axis (150) of the bore.

Systems and methods for shuttle mode radiation delivery are described herein. One method for radiation delivery comprises moving the patient platform through the patient treatment region multiple times during a treatment session. This may be referred to as patient platform or couch shuttling (i.e., couch shuttle mode). Another method for radiation delivery comprises moving the therapeutic radiation source jaw across a range of positions during a treatment session. The jaw may move across the same range of positions multiple times during a treatment session. This may be referred to as jaw shuttling (i.e., jaw shuttle mode). Some methods combine couch shuttle mode and jaw shuttle mode. Methods of dynamic or pipelined normalization are also described.

The application relates to application of a molecular medicine in prevention or treatment of systemic damage induced by radiation (especially ionizing radiation with greater damage). The application research shows that a small molecule medicine MEC1 can improve the overall survival state of an ionizing radiation subject, significantly prolong the survival time of the radiation subject, reduce weight loss, reduce damage of multiple organ tissues such as thymus, spleen, small intestine, lung, skin, liver, kidney, muscle, heart and brain tissue, and show obvious protection, and can improve hematological, serum biochemical and immune homeostasis abnormalities, improve blood routine and serum biochemical abnormalities, relieve imbalance of B / m ratio, and show improvement or improvement trend on neurological behavior abnormalities and heart function changes, and can be used for prevention, reduction or treatment of systemic damage induced by ionizing radiation, and provides wide protection on multiple organs and tissues. Moreover, the small molecule has high safety, and has important and wide application value in anti-radiation products and radiation damage repair products.

The invention relates to a laser treatment device (1) comprising a device base (26), an application arm (12) fastened to the device base (26) and a laser light source (28) for generating treatment radiation (30), the application arm (12) having at least one working position (32) in which the application arm (12) is designed to guide the treatment radiation (30) into a processing region (22). Known laser treatment devices (1) have the disadvantage that the pre-positioning (P1) must be repeated when incorrectly performed, thereby increasing preparation time and reducing patient comfort. According to the invention, this is improved in that the laser treatment device (1) also has a projection unit (6) for simplifying the positioning of the person (22b) to be treated relative to the laser treatment device (1), and the projection unit (6) is designed to project a positioning mark (20) in such a way that the positioning mark represents the position of the processing region (22).

A method for performing ablative radiotherapy includes registering a first coordinate system of a tracking system for tracking a distal end of an intra-body catheter with a second coordinate system of a beam-directing system, tracking the location of a distal end of the catheter, receiving instructions from a user to ablate target tissue within the body with the beam-directing system and based on the registration and the tracking, aiming the beam-directing system at the target tissue so as to facilitate directing the therapeutic beams of radiation at the target tissue.

Embodiments of the present specification provide a treatment apparatus comprising a magnetic resonance imaging (MRI) apparatus for acquiring MRI data regarding a region of interest (ROI), and a radiotherapy apparatus, where the MRI apparatus comprises an annular cryostat comprising: one or more chambers arranged along an axis of the annular cryostat; the annular structure device surrounds the one or more cavities, the annular structure device comprises a plurality of annular structures, and the radiation beams penetrate through the annular structures; the degree of scattering of the radiation beam through the annular cryostat is reduced by reducing the effective thickness of the annular cryostat and / or controlling the depth of the cooling medium contained in the one or more chambers; the radiotherapy device is used to apply therapeutic radiation to at least a portion of the ROI.

The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.

Disclosed herein is an imaging system for a radiotherapy device which is configured to provide therapeutic radiation to a patient via a source of therapeutic radiation. The imaging system comprises a source of imaging radiation, a CBCT panel detector, and a CT detector, wherein the source of imaging radiation is configured to be adjustable such that in a first configuration it is configured to emit imaging radiation towards the CT detector and in a second configuration it is configured to emit imaging radiation towards the CBCT detector.

Disclosed is use of Cordyceps sinensis in the preparation of a health product or drug for preventing and / or treating radiation injury, particularly in the preparation of a health product or drug for preventing and / or treating intestinal radiation injury caused by ionizing radiation. Specifically, Cordyceps sinensis can significantly ameliorate symptoms caused by intestinal radiation injury, such as weight loss, shortened colon length, elevated ROS content in blood and / or small intestine, elevated inflammation levels in blood and / or small intestine, and small intestine tissue injury.